Advertisement

Topics

Seattle Genetics Discontinues Late-Stage Acute Myeloid Leukemia Trial due to Safety Concerns

09:29 EDT 19 Jun 2017 | Speciality Pharma Journal

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients. Seattle Genetics took this action following consultation with the Independent Data Monitoring Committee (IDMC) and after reviewing unblinded data on …

Original Article: Seattle Genetics Discontinues Late-Stage Acute Myeloid Leukemia Trial due to Safety Concerns

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Discontinues Late-Stage Acute Myeloid Leukemia Trial due to Safety Concerns"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...